ClinicalTrials.Veeva

Menu

Comparison of Ventricular Tachycardia Ablation Strategies in Patients With Ischemic Cardiomyopathy (EPI-VT)

Montefiore Medicine Academic Health System logo

Montefiore Medicine Academic Health System

Status and phase

Withdrawn
Early Phase 1

Conditions

Ventricular Tachycardia

Treatments

Procedure: Endocardial ablation
Procedure: Endocardial- Epicardial ablation
Drug: Antiarrhythmic medications

Study type

Interventional

Funder types

Other

Identifiers

NCT04512911
2019-10639

Details and patient eligibility

About

This is a prospective multicenter randomized open-label study aiming to assess whether endocardial or endocardial-epicardial ablation is superior to the standard approach (i.e., Antiarrhythmic drugs) in achievement of long-term ventricular tachycardia (VT) treatment success.

Full description

Comparison of Ventricular Tachycardia Ablation Strategies in Patients With Ischemic Cardiomyopathy (EPI VT) is a prospective multicenter randomized controlled study that is planned as a pilot study to include 100 patients. The aim of our study is to assess whether endocardial or endocardial-epicardial ablation is superior to the standard approach (i.e., Antiarrhythmic drugs) in the achievement of long-term ventricular tachycardia (VT) treatment success. Patients will be stratified into two groups depending on the history of taking antiarrhythmic medications (AAD) and each group will be further randomized 1:1 for endocardial and epicardial ablation vs endocardial only ablation in group who failed AAD. And in the group who didn't fail AADs patients will be randomized 1:1:1 into 3 groups: endocardial and epicardial ablation, endocardial only ablation or antiarrhythmic medications. Follow up planned at 3, 6 and 12 months, if VT recurrence is noted, repeated procedure (according to initially allocated group) or adjustment of medications (if AAD group) will be performed. Follow up at 3, 6 and 12 months is also planned after a repeat procedure/ medications adjustment.

Primary endpoints include freedom from documented VT episodes (> 30 seconds) at 12 months after the first ablation procedure or on antiarrhythmic medication and freedom from documented VT episodes (>30 seconds) at 12 months after the second ablation procedure or on two antiarrhythmics combined.

Sex

All

Ages

18 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged 18 or greater
  • Patient with ≥ 1 episode of VT (i.e., Sustained VT more than 30 seconds or VT with any ICD therapy)
  • Patients with ischemic cardiomyopathy, EF less than 50%, documented history of CAD

Exclusion criteria

  • Patients with ventricular fibrillation.

  • Reversible causes of VT.

  • Patients with contraindications to systemic anticoagulation with heparin or coumadin, direct thrombin inhibitor or factor Xa inhibitors.

  • Patients with prior procedure involving opening the pericardium or entering the pericardial space (e.g., CABG, heart transplantation, valve surgery) were adhesions are suspected

  • Any prior ablation for the ventricles or any prior epicardial ablation

  • Documented history of myocardial infarction within 1 month prior to the planned study intervention

  • Documented symptomatic carotid disease defined as > 70% stenosis or > 50% stenosis with symptoms

  • Any history of thoracic radiation with the exception of localized radiation treatment for breast cancer

  • Active pericarditis

  • Active endocarditis\Any documented history or autoimmune disease associated with pericarditis

  • Thrombocytopenia (platelet count < 100 x 109/L)

  • Body Mass Index (BMI > 45)

  • Patients who are pregnant.

    1. Pregnancy will be assessed by urine pregnancy testing prior to the ablation procedure

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

0 participants in 2 patient groups

Patients who didn't fail AAD
Active Comparator group
Description:
This group of patients will be randomized to 3 subgroups: 1) Endocardial ablation; 2) Endocardial - Epicardial ablation; 3) Antiarrhythmic medications
Treatment:
Drug: Antiarrhythmic medications
Procedure: Endocardial ablation
Procedure: Endocardial- Epicardial ablation
Patients who failed AAD
Active Comparator group
Description:
This group of patients will be randomized to 2 subgroups: 1) Endocardial ablation; 2) Endocardial - Epicardial ablation
Treatment:
Procedure: Endocardial ablation
Procedure: Endocardial- Epicardial ablation

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems